BioMarin and institute will research early-onset Alzheimer's

08/16/2010 | American City Business Journals

BioMarin Pharmaceutical agreed to collaborate with the Buck Institute for Age Research to discover treatments for early-onset familial Alzheimer's disease, a hereditary condition in which Alzheimer's symptoms appear in people as early as their 30s. The deal calls for BioMarin to provide financial backing for the partnership for as long as two years.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX